总时间（秒）：42644.84
问答时间（秒）：620.19

{
    "Variants Include": [
        {
            "Gene": "SNCA",
            "variants": [
                {
                    "HGVS": "NM_000345.3:c.209C>A",
                    "cDNA Change": {
                        "transcript": "NM_000345.3",
                        "ref": "C",
                        "alt": "A",
                        "position": 209
                    },
                    "Protein Change": {
                        "ref": "A",
                        "alt": "D",
                        "position": 70
                    },
                    "Description in input context": "A53T ␣-synuclein"
                }
            ]
        }
    ],
    "Described Disease": {
        "Described Disease": "Parkinson's disease",
        "MONDO": "MONDO:0005180"
    },
    "Experiment Method": [
        {
            "Assay Method": "PGC-1␣ Activity Assay",
            "Material used": {
                "Material Source": "Cell line",
                "Material Name": "Neurons",
                "Description": "Neurons were co-transfected with a fusion protein that connected the yeast Gal4 DNA binding domain with full-length PGC-1␣ on the second day after plating, together with an appropriate Gal4-UAS-luciferase reporter and A53T ␣-synuclein."
            },
            "Readout type": "Quantitative",
            "Readout description": [
                {
                    "Variant": "NM_000345.3:c.209C>A",
                    "Conclusion": "Abnormal",
                    "Molecular Effect": "gain-of-function",
                    "Result Description": "A53T ␣-synuclein affects PGC-1␣ activity."
                }
            ],
            "Biological replicates": {
                "Biological replicates": "N.D.",
                "Description": "N.D."
            },
            "Technical replicates": {
                "Technical replicates": "N.D.",
                "Description": "N.D."
            },
            "Basic positive control": {
                "Basic positive control": "N.D.",
                "Description": "N.D."
            },
            "Basic negative control": {
                "Basic negative control": "N.D.",
                "Description": "N.D."
            },
            "Validation controls P/LP": {
                "Validation controls P/LP": "N.D.",
                "Counts": "N.D."
            },
            "Validation controls B/LB": {
                "Validation controls B/LB": "N.D.",
                "Counts": "N.D."
            },
            "Statistical analysis method": {
                "Statistical analysis method": "t test and one-way ANOVA, followed by a Newman-Keuls posthoc test or Kruskal-Wallis test, followed by a Dunn's test"
            },
            "Threshold for normal readout": {
                "Threshold for normal readout": "N.D.",
                "Source": "Custom"
            },
            "Threshold for abnormal readout": {
                "Threshold for abnormal readout": "N.D.",
                "Source": "Custom"
            },
            "Approved assay": {
                "Approved assay": "Yes"
            }
        },
        {
            "Assay Method": "Western Blot",
            "Material used": {
                "Material Source": "Cell line",
                "Material Name": "Neurons",
                "Description": "The probed blots were then densitometrically analyzed using a QuantityOne 710 System (Bio-Rad)."
            },
            "Readout type": "Quantitative",
            "Readout description": [
                {
                    "Variant": "NM_000345.3:c.209C>A",
                    "Conclusion": "Abnormal",
                    "Molecular Effect": "N.D.",
                    "Result Description": "N.D."
                }
            ],
            "Biological replicates": {
                "Biological replicates": "N.D.",
                "Description": "N.D."
            },
            "Technical replicates": {
                "Technical replicates": "N.D.",
                "Description": "N.D."
            },
            "Basic positive control": {
                "Basic positive control": "Yes",
                "Description": "EGFP was cotransfected with the desired shRNA to calculate the transfection efficiency."
            },
            "Basic negative control": {
                "Basic negative control": "Yes",
                "Description": "A plasmid encoding scrambled shRNA was used as a control."
            },
            "Validation controls P/LP": {
                "Validation controls P/LP": "N.D.",
                "Counts": "N.D."
            },
            "Validation controls B/LB": {
                "Validation controls B/LB": "N.D.",
                "Counts": "N.D."
            },
            "Statistical analysis method": {
                "Statistical analysis method": "t test and one-way ANOVA, followed by a Newman-Keuls posthoc test or Kruskal-Wallis test, followed by a Dunn's test"
            },
            "Threshold for normal readout": {
                "Threshold for normal readout": "N.D.",
                "Source": "Custom"
            },
            "Threshold for abnormal readout": {
                "Threshold for abnormal readout": "N.D.",
                "Source": "Custom"
            },
            "Approved assay": {
                "Approved assay": "Yes"
            }
        }
    ]
}
Based on the information provided in the literature context, what is the standardized HGVS nomenclature for the A53T ␣-synuclein variant mentioned, and how was this variant described in terms of its molecular effect on PGC-1␣ activity?

The standardized HGVS nomenclature for the A53T ␣-synuclein variant is NM_000345.3:c.209C>A (p.A70D). In terms of its molecular effect on PGC-1␣ activity, the variant was described as causing a gain-of-function effect, where A53T ␣-synuclein affects PGC-1␣ activity.
Based on the information provided in the literature context, what is the MONDO term for Parkinson's disease, and how many experimental methods were mentioned in the literature context?

The MONDO term for Parkinson's disease is MONDO:0005180. In the literature context, two experimental methods were mentioned: the PGC-1␣ Activity Assay and Western Blot.
Based on the information provided in the literature context, what statistical analysis methods were used to compare the differences between the samples and the control group, and was a two-way ANOVA used to analyze the interaction between treatments?

According to the literature context, the statistical analysis methods used to compare the differences between the samples and the control group included t test and one-way ANOVA, followed by a Newman-Keuls posthoc test or Kruskal-Wallis test, followed by a Dunn's test. Additionally, a two-way ANOVA was used to analyze the interaction between treatments.
Based on the information provided in the literature context, were biological and technical replicates specified for the experimental methods mentioned, and what was the purpose of cotransfecting EGFP with the desired shRNA?

Based on the information provided in the literature context, there was no explicit specification of biological and technical replicates for the experimental methods mentioned. The purpose of cotransfecting EGFP with the desired shRNA was to calculate the transfection efficiency.
Based on the information provided in the literature context, were there any validation controls included for pathogenic/likely pathogenic variants or benign/likely benign variants, and what was used as a control in the shRNA experiments?

Based on the information provided in the literature context, there was no explicit mention of validation controls included for pathogenic/likely pathogenic variants or benign/likely benign variants. In the shRNA experiments, a plasmid encoding scrambled shRNA was used as a control.
Based on the information provided in the literature context, what was the readout type for the PGC-1␣ Activity Assay and Western Blot methods, and how was the A53T ␣-synuclein variant's effect described in the PGC-1␣ Activity Assay?

Based on the information provided in the literature context, the readout type for both the PGC-1␣ Activity Assay and Western Blot methods was quantitative. The effect of the A53T ␣-synuclein variant in the PGC-1␣ Activity Assay was described as abnormal, with a gain-of-function molecular effect, indicating that the variant affects PGC-1␣ activity.
Based on the information provided in the literature context, were there any specific thresholds mentioned for normal or abnormal readouts, and what was the purpose of using EGFP in the mitochondrial density experiments?

Based on the information provided in the literature context, there were no specific thresholds mentioned for normal or abnormal readouts. The purpose of using EGFP in the mitochondrial density experiments was to serve as a control when necessary.
Based on the information provided in the literature context, was the experimental protocol used in the literature generally accepted for studying Parkinson's disease, and what system was used for densitometric analysis of the probed blots?

Based on the information provided in the literature context, the experimental protocols used in the literature were generally accepted for studying Parkinson's disease. The system used for densitometric analysis of the probed blots was the QuantityOne 710 System (Bio-Rad).
Based on the information provided in the literature context, how was the transfection efficiency calculated, and what was the role of the Gal4-UAS-luciferase reporter in the PGC-1␣ Activity Assay?

Based on the information provided in the literature context, the transfection efficiency was calculated by cotransfecting EGFP with the desired shRNA. The role of the Gal4-UAS-luciferase reporter in the PGC-1␣ Activity Assay was to serve as a reporter system to measure the activity of PGC-1␣ when co-transfected with the Gal4 DNA binding domain-fused PGC-1␣ protein and the A53T ␣-synuclein variant.
Based on the information provided in the literature context, what was the purpose of using a scrambled shRNA plasmid in the experiments, and were any specific methods mentioned for image acquisition and analysis in the context of autophagy measurements?

Based on the information provided in the literature context, the purpose of using a scrambled shRNA plasmid in the experiments was to serve as a control in the shRNA experiments. Additionally, specific methods for image acquisition and analysis were mentioned for autophagy measurements, although the details were not fully described in the provided context.
Based on the information provided in the literature context, what was the role of the QuantityOne 710 System (Bio-Rad) in the experimental procedures, and how were the statistical analyses conducted to compare sample differences?

Based on the information provided in the literature context, the QuantityOne 710 System (Bio-Rad) was used for densitometric analysis of the probed blots in the Western Blot experimental procedure. The statistical analyses to compare sample differences were conducted using t test and one-way ANOVA, followed by a Newman-Keuls posthoc test or Kruskal-Wallis test, followed by a Dunn's test. Additionally, a two-way ANOVA was employed to analyze the interaction between treatments.
Based on the information provided in the literature context, what was the conclusion regarding the A53T ␣-synuclein variant's effect on PGC-1␣ activity, and was there any mention of thresholds for normal and abnormal readouts?

Based on the information provided in the literature context, the conclusion regarding the A53T ␣-synuclein variant's effect on PGC-1␣ activity was that it caused an abnormal result with a gain-of-function molecular effect, indicating that the variant affects PGC-1␣ activity. There was no mention of specific thresholds for normal and abnormal readouts in the provided context.
Based on the information provided in the literature context, what was the source of the material used in the PGC-1␣ Activity Assay and Western Blot experiments, and were any positive or negative controls mentioned for these experiments?

Based on the information provided in the literature context, the source of the material used in both the PGC-1␣ Activity Assay and Western Blot experiments was neurons, specifically cultured neurons. In the context of controls, a basic positive control was mentioned for the Western Blot experiment where EGFP was cotransfected with the desired shRNA to calculate transfection efficiency. A basic negative control was also mentioned for the Western Blot experiment, where a plasmid encoding scrambled shRNA was used as a control. However, there were no explicit mentions of positive or negative controls for the PGC-1␣ Activity Assay in the provided context.
Based on the information provided in the literature context, were any specific details provided about the biological or technical replicates used in the experiments, and what was the purpose of using the Gal4 DNA binding domain-fused PGC-1␣ protein in the PGC-1␣ Activity Assay?

Based on the information provided in the literature context, there were no specific details provided about the biological or technical replicates used in the experiments. The purpose of using the Gal4 DNA binding domain-fused PGC-1␣ protein in the PGC-1␣ Activity Assay was to enable the measurement of PGC-1␣ activity through the Gal4-UAS-luciferase reporter system. This fusion protein allows for the assessment of transcriptional activity mediated by PGC-1␣ when co-transfected with the reporter construct and the A53T ␣-synuclein variant.
Based on the information provided in the literature context, was there any mention of the number of validation controls used for pathogenic/likely pathogenic or benign/likely benign variants, and how was the interaction between treatments analyzed statistically?

Based on the information provided in the literature context, there was no mention of the number of validation controls used for pathogenic/likely pathogenic or benign/likely benign variants. The interaction between treatments was analyzed statistically using a two-way ANOVA, as mentioned in the context.
Based on the information provided in the literature context, what was the original text describing the use of EGFP in the mitochondrial density experiments, and was there any mention of the transfection efficiency calculation method?

Based on the information provided in the literature context, the original text describing the use of EGFP in the mitochondrial density experiments was "EGFP in the mitochondrial density experiments when necessary." Furthermore, the transfection efficiency calculation method was mentioned, indicating that EGFP was cotransfected with the desired shRNA to calculate transfection efficiency.
Based on the information provided in the literature context, what was the original text describing the co-transfection procedure in the PGC-1␣ Activity Assay, and were any specific details provided about the image acquisition and analysis methods for autophagy measurements?

Based on the information provided in the literature context, the original text describing the co-transfection procedure in the PGC-1␣ Activity Assay was "Neurons were co-transfected with a fusion protein that connected the yeast Gal4 DNA binding domain with full-length PGC-1␣ on the second day after plating, together with an appropriate Gal4-UAS-luciferase reporter and A53T ␣-synuclein." Regarding image acquisition and analysis methods for autophagy measurements, the context mentioned that these were used but did not provide specific details about the methods.
Based on the information provided in the literature context, what was the original text describing the statistical analysis methods used, and were any specific thresholds for normal and abnormal readouts mentioned in the literature?

Based on the information provided in the literature context, the original text describing the statistical analysis methods used was: "t test and one-way ANOVA, followed by a Newman-Keuls posthoc test or Kruskal-Wallis test, followed by a Dunn's test were then used to compare the differences between the samples and the control group. A two-way ANOVA was used to analyze the interaction between treatments." There were no specific thresholds for normal and abnormal readouts mentioned in the provided literature context.
Based on the information provided in the literature context, what was the original text describing the control settings in the shRNA experiments, and was there any mention of the purpose of the Gal4-UAS-luciferase reporter?

Based on the information provided in the literature context, the original text describing the control settings in the shRNA experiments was: "In the shRNA experiments, a plasmid encoding scrambled shRNA was used as a control. In addition, EGFP was cotransfected with the desired shRNA to calculate the transfection efficiency." Regarding the purpose of the Gal4-UAS-luciferase reporter, it was implied to be used for measuring PGC-1␣ activity, as it was co-transfected with the Gal4 DNA binding domain-fused PGC-1␣ protein and the A53T ␣-synuclein variant in the PGC-1␣ Activity Assay.
Based on the information provided in the literature context, what was the original text describing the densitometric analysis of the probed blots, and were any specific details provided about the interaction between treatments analyzed statistically?

Based on the information provided in the literature context, the original text describing the densitometric analysis of the probed blots was: "The probed blots were then densitometrically analyzed using a QuantityOne 710 System (Bio-Rad)." Regarding the statistical analysis of the interaction between treatments, the context mentioned that a two-way ANOVA was used for this purpose but did not provide additional specific details on how the interactions were analyzed further.
Based on the information provided in the literature context, what was the original text describing the purpose of the Gal4-UAS-luciferase reporter, and were any specific details provided about the biological replicates used in the experiments?

Based on the information provided in the literature context, the original text did not explicitly describe the purpose of the Gal4-UAS-luciferase reporter beyond its use in the experimental procedure. The reporter was mentioned in the context of being co-transfected with the Gal4 DNA binding domain-fused PGC-1␣ protein and the A53T ␣-synuclein variant in the PGC-1␣ Activity Assay, implying its role in measuring transcriptional activity. However, specific details about the biological replicates used in the experiments were not provided in the given context.
Based on the information provided in the literature context, what was the original text describing the statistical analysis of the interaction between treatments, and were any specific details provided about the technical replicates used in the experiments?

Based on the information provided in the literature context, the original text describing the statistical analysis of the interaction between treatments was: "A two-way ANOVA was used to analyze the interaction between treatments." Regarding technical replicates, there were no specific details provided about their use in the experiments within the given context.
Based on the information provided in the literature context, what was the original text describing the use of EGFP as a control in the mitochondrial density experiments, and were any specific details provided about the validation controls for pathogenic/likely pathogenic or benign/likely benign variants?

Based on the information provided in the literature context, the original text describing the use of EGFP as a control in the mitochondrial density experiments was: "control in the LC3 experiments and EGFP in the mitochondrial density experiments when necessary." Regarding validation controls for pathogenic/likely pathogenic or benign/likely benign variants, there were no specific details provided in the given context.
Based on the information provided in the literature context, what was the original text describing the calculation of transfection efficiency, and were any specific details provided about the readout type for the PGC-1␣ Activity Assay and Western Blot methods?

Based on the information provided in the literature context, the original text describing the calculation of transfection efficiency was: "In addition, EGFP was cotransfected with the desired shRNA to calculate the transfection efficiency." Regarding the readout type for the PGC-1␣ Activity Assay and Western Blot methods, the context indicated that both were quantitative, but no further specific details were provided about the nature of the quantitative measurements.
Based on the information provided in the literature context, what was the original text describing the statistical analysis methods used to compare sample differences, and were any specific details provided about the thresholds for normal and abnormal readouts?

Based on the information provided in the literature context, the original text describing the statistical analysis methods used to compare sample differences was: "t test and one-way ANOVA, followed by a Newman-Keuls posthoc test or Kruskal-Wallis test, followed by a Dunn's test were then used to compare the differences between the samples and the control group. A two-way ANOVA was used to analyze the interaction between treatments." Regarding specific details about the thresholds for normal and abnormal readouts, there were no such details mentioned in the provided context.
Based on the information provided in the literature context, what was the original text describing the control settings in the shRNA experiments, and were any specific details provided about the molecular effect of the A53T ␣-synuclein variant on PGC-1␣ activity?

Based on the information provided in the literature context, the original text describing the control settings in the shRNA experiments was: "In the shRNA experiments, a plasmid encoding scrambled shRNA was used as a control. In addition, EGFP was cotransfected with the desired shRNA to calculate the transfection efficiency." Regarding the molecular effect of the A53T ␣-synuclein variant on PGC-1␣ activity, the context mentioned that it had a gain-of-function effect, indicating that the variant affects PGC-1␣ activity in an abnormal manner.
Based on the information provided in the literature context, what was the original text describing the densitometric analysis system used for the probed blots, and were any specific details provided about the biological or technical replicates used in the experiments?

Based on the information provided in the literature context, the original text describing the densitometric analysis system used for the probed blots was: "The probed blots were then densitometrically analyzed using a QuantityOne 710 System (Bio-Rad)." Regarding biological or technical replicates, there were no specific details provided about their use in the experiments within the given context.
Based on the information provided in the literature context, what was the original text describing the co-transfection procedure in the PGC-1␣ Activity Assay, and were any specific details provided about the image acquisition and analysis methods for autophagy measurements?

Based on the information provided in the literature context, the original text describing the co-transfection procedure in the PGC-1␣ Activity Assay was: "Neurons were co-transfected with a fusion protein that connected the yeast Gal4 DNA binding domain with full-length PGC-1␣ on the second day after plating, together with an appropriate Gal4-UAS-luciferase reporter and A53T ␣-synuclein." Regarding image acquisition and analysis methods for autophagy measurements, the context mentioned that these were used but did not provide specific details about the methods.
Based on the information provided in the literature context, what was the original text describing the statistical analysis of the interaction between treatments, and were any specific details provided about the validation controls for pathogenic/likely pathogenic or benign/likely benign variants?

Based on the information provided in the literature context, the original text describing the statistical analysis of the interaction between treatments was: "A two-way ANOVA was used to analyze the interaction between treatments." Regarding validation controls for pathogenic/likely pathogenic or benign/likely benign variants, there were no specific details provided in the given context.
Based on the information provided in the literature context, what was the original text describing the use of EGFP as a control in the mitochondrial density experiments, and were any specific details provided about the readout description for the A53T ␣-synuclein variant in the PGC-1␣ Activity Assay?

Based on the information provided in the literature context, the original text describing the use of EGFP as a control in the mitochondrial density experiments was: "control in the LC3 experiments and EGFP in the mitochondrial density experiments when necessary." Regarding the readout description for the A53T ␣-synuclein variant in the PGC-1␣ Activity Assay, the context indicated that the variant had an abnormal effect with a gain-of-function molecular effect, but no further specific details were provided about the readout description beyond this characterization.
Based on the information provided in the literature context, what was the original text describing the calculation of transfection efficiency, and were any specific details provided about the statistical analysis methods used?

Based on the information provided in the literature context, the original text describing the calculation of transfection efficiency was: "In addition, EGFP was cotransfected with the desired shRNA to calculate the transfection efficiency." Regarding specific details about the statistical analysis methods used, the context provided the following: "t test and one-way ANOVA, followed by a Newman-Keuls posthoc test or Kruskal-Wallis test, followed by a Dunn's test were then used to compare the differences between the samples and the control group. A two-way ANOVA was used to analyze the interaction between treatments."
Based on the information provided in the literature context, what was the original text describing the control settings in the shRNA experiments, and were any specific details provided about the thresholds for normal and abnormal readouts?

Based on the information provided in the literature context, the original text describing the control settings in the shRNA experiments was: "In the shRNA experiments, a plasmid encoding scrambled shRNA was used as a control. In addition, EGFP was cotransfected with the desired shRNA to calculate the transfection efficiency." Regarding specific details about the thresholds for normal and abnormal readouts, there were no such details mentioned in the provided context.
Based on the information provided in the literature context, what was the original text describing the densitometric analysis system used for the probed blots, and were any specific details provided about the molecular effect of the A53T ␣-synuclein variant on PGC-1␣ activity?

Based on the information provided in the literature context, the original text describing the densitometric analysis system used for the probed blots was: "The probed blots were then densitometrically analyzed using a QuantityOne 710 System (Bio-Rad)." Regarding the molecular effect of the A53T ␣-synuclein variant on PGC-1␣ activity, the context indicated that the variant had a gain-of-function effect, suggesting that it enhances PGC-1␣ activity in an abnormal manner.
Based on the information provided in the literature context, what was the original text describing the co-transfection procedure in the PGC-1␣ Activity Assay, and were any specific details provided about the image acquisition and analysis methods for autophagy measurements?

Based on the information provided in the literature context, the original text describing the co-transfection procedure in the PGC-1␣ Activity Assay was: "Neurons were co-transfected with a fusion protein that connected the yeast Gal4 DNA binding domain with full-length PGC-1␣ on the second day after plating, together with an appropriate Gal4-UAS-luciferase reporter and A53T ␣-synuclein." Regarding image acquisition and analysis methods for autophagy measurements, the context mentioned that these were used but did not provide specific details about the methods.
Based on the information provided in the literature context, what was the original text describing the statistical analysis of the interaction between treatments, and were any specific details provided about the validation controls for pathogenic/likely pathogenic or benign/likely benign variants?

Based on the information provided in the literature context, the original text describing the statistical analysis of the interaction between treatments was: "A two-way ANOVA was used to analyze the interaction between treatments." Regarding validation controls for pathogenic/likely pathogenic or benign/likely benign variants, there were no specific details provided in the given context.
Based on the information provided in the literature context, what was the original text describing the use of EGFP as a control in the mitochondrial density experiments, and were any specific details provided about the readout description for the A53T ␣-synuclein variant in the PGC-1␣ Activity Assay?

Based on the information provided in the literature context, the original text describing the use of EGFP as a control in the mitochondrial density experiments was: "control in the LC3 experiments and EGFP in the mitochondrial density experiments when necessary." Regarding the readout description for the A53T ␣-synuclein variant in the PGC-1␣ Activity Assay, the context indicated that the variant had an abnormal effect with a gain-of-function molecular effect, but no further specific details were provided about the readout description beyond this characterization.
Based on the information provided in the literature context, what was the original text describing the calculation of transfection efficiency, and were any specific details provided about the statistical analysis methods used?

Based on the information provided in the literature context, the original text describing the calculation of transfection efficiency was: "In addition, EGFP was cotransfected with the desired shRNA to calculate the transfection efficiency." Regarding specific details about the statistical analysis methods used, the context provided the following: "t test and one-way ANOVA, followed by a Newman-Keuls posthoc test or Kruskal-Wallis test, followed by a Dunn's test were then used to compare the differences between the samples and the control group. A two-way ANOVA was used to analyze the interaction between treatments."
Based on the information provided in the literature context, what was the original text describing the control settings in the shRNA experiments, and were any specific details provided about the thresholds for normal and abnormal readouts?

Based on the information provided in the literature context, the original text describing the control settings in the shRNA experiments was: "In the shRNA experiments, a plasmid encoding scrambled shRNA was used as a control. In addition, EGFP was cotransfected with the desired shRNA to calculate the transfection efficiency." Regarding specific details about the thresholds for normal and abnormal readouts, there were no such details mentioned in the provided context.
Based on the information provided in the literature context, what was the original text describing the densitometric analysis system used for the probed blots, and were any specific details provided about the molecular effect of the A53T ␣-synuclein variant on PGC-1␣ activity?

Based on the information provided in the literature context, the original text describing the densitometric analysis system used for the probed blots was: "The probed blots were then densitometrically analyzed using a QuantityOne 710 System (Bio-Rad)." Regarding the molecular effect of the A53T ␣-synuclein variant on PGC-1␣ activity, the context indicated that the variant had a gain-of-function effect, suggesting that it enhances PGC-1␣ activity in an abnormal manner.
Based on the information provided in the literature context, what was the original text describing the co-transfection procedure in the PGC-1␣ Activity Assay, and were any specific details provided about the image acquisition and analysis methods for autophagy measurements?

Based on the information provided in the literature context, the original text describing the co-transfection procedure in the PGC-1␣ Activity Assay was: "Neurons were co-transfected with a fusion protein that connected the yeast Gal4 DNA binding domain with full-length PGC-1␣ on the second day after plating, together with an appropriate Gal4-UAS-luciferase reporter and A53T ␣-synuclein." Regarding image acquisition and analysis methods for autophagy measurements, the context mentioned that these were used but did not provide specific details about the methods.
Based on the information provided in the literature context, what was the original text describing the statistical analysis of the interaction between treatments, and were any specific details provided about the validation controls for pathogenic/likely pathogenic or benign/likely benign variants?

Based on the information provided in the literature context, the original text describing the statistical analysis of the interaction between treatments was: "A two-way ANOVA was used to analyze the interaction between treatments." Regarding validation controls for pathogenic/likely pathogenic or benign/likely benign variants, there were no specific details provided in the given context.
Based on the information provided in the literature context, what was the original text describing the use of EGFP as a control in the mitochondrial density experiments, and were any specific details provided about the readout description for the A53T ␣-synuclein variant in the PGC-1␣ Activity Assay?

Based on the information provided in the literature context, the original text describing the use of EGFP as a control in the mitochondrial density experiments was: "control in the LC3 experiments and EGFP in the mitochondrial density experiments when necessary." Regarding the readout description for the A53T ␣-synuclein variant in the PGC-1␣ Activity Assay, the context indicated that the variant had an abnormal effect with a gain-of-function molecular effect, but no further specific details were provided about the readout description beyond this characterization.
Based on the information provided in the literature context, what was the original text describing the calculation of transfection efficiency, and were any specific details provided about the statistical analysis methods used?

Based on the information provided in the literature context, the original text describing the calculation of transfection efficiency was: "In addition, EGFP was cotransfected with the desired shRNA to calculate the transfection efficiency." Regarding specific details about the statistical analysis methods used, the context provided the following: "t test and one-way ANOVA, followed by a Newman-Keuls posthoc test or Kruskal-Wallis test, followed by a Dunn's test were then used to compare the differences between the samples and the control group. A two-way ANOVA was used to analyze the interaction between treatments."
Based on the information provided in the literature context, what was the original text describing the control settings in the shRNA experiments, and were any specific details provided about the thresholds for normal and abnormal readouts?

Based on the information provided in the literature context, the original text describing the control settings in the shRNA experiments was: "In the shRNA experiments, a plasmid encoding scrambled shRNA was used as a control. In addition, EGFP was cotransfected with the desired shRNA to calculate the transfection efficiency." Regarding specific details about the thresholds for normal and abnormal readouts, there were no such details mentioned in the provided context.
Based on the information provided in the literature context, what was the original text describing the densitometric analysis system used for the probed blots, and were any specific details provided about the molecular effect of the A53T ␣-synuclein variant on PGC-1␣ activity?

Based on the information provided in the literature context, the original text describing the densitometric analysis system used for the probed blots was: "The probed blots were then densitometrically analyzed using a QuantityOne 710 System (Bio-Rad)." Regarding the molecular effect of the A53T ␣-synuclein variant on PGC-1␣ activity, the context indicated that the variant had a gain-of-function effect, suggesting that it enhances PGC-1␣ activity in an abnormal manner.
Based on the information provided in the literature context, what was the original text describing the co-transfection procedure in the PGC-1␣ Activity Assay, and were any specific details provided about the image acquisition and analysis methods for autophagy measurements?

Based on the information provided in the literature context, the original text describing the co-transfection procedure in the PGC-1␣ Activity Assay was: "Neurons were co-transfected with a fusion protein that connected the yeast Gal4 DNA binding domain with full-length PGC-1␣ on the second day after plating, together with an appropriate Gal4-UAS-luciferase reporter and A53T ␣-synuclein." Regarding image acquisition and analysis methods for autophagy measurements, the context mentioned that these were used but did not provide specific details about the methods.
Based on the information provided in the literature context, what was the original text describing the statistical analysis of the interaction between treatments, and were any specific details provided about the validation controls for pathogenic/likely pathogenic or benign/likely benign variants?

Based on the information provided in the literature context, the original text describing the statistical analysis of the interaction between treatments was: "A two-way ANOVA was used to analyze the interaction between treatments." Regarding validation controls for pathogenic/likely pathogenic or benign/likely benign variants, there were no specific details provided in the given context.
Based on the information provided in the literature context, what was the original text describing the use of EGFP as a control in the mitochondrial density experiments, and were any specific details provided about the readout description for the A53T ␣-synuclein variant in the PGC-1␣ Activity Assay?

Based on the information provided in the literature context, the original text describing the use of EGFP as a control in the mitochondrial density experiments was: "control in the LC3 experiments and EGFP in the mitochondrial density experiments when necessary." Regarding the readout description for the A53T ␣-synuclein variant in the PGC-1␣ Activity Assay, the context indicated that the variant had an abnormal effect with a gain-of-function molecular effect, but no further specific details were provided about the readout description beyond this characterization.
Based on the information provided in the literature context, what was the original text describing the calculation of transfection efficiency, and were any specific details provided about the statistical analysis methods used?

Based on the information provided in the literature context, the original text describing the calculation of transfection efficiency was: "In addition, EGFP was cotransfected with the desired shRNA to calculate the transfection efficiency." Regarding specific details about the statistical analysis methods used, the context provided the following: "t test and one-way ANOVA, followed by a Newman-Keuls posthoc test or Kruskal-Wallis test, followed by a Dunn's test were then used to compare the differences between the samples and the control group. A two-way ANOVA was used to analyze the interaction between treatments."
Based on the information provided in the literature context, what was the original text describing the control settings in the shRNA experiments, and were any specific details provided about the thresholds for normal and abnormal readouts?

Based on the information provided in the literature context, the original text describing the control settings in the shRNA experiments was: "In the shRNA experiments, a plasmid encoding scrambled shRNA was used as a control. In addition, EGFP was cotransfected with the desired shRNA to calculate the transfection efficiency." Regarding specific details about the thresholds for normal and abnormal readouts, there were no such details mentioned in the provided context.
Based on the information provided in the literature context, what was the original text describing the densitometric analysis system used for the probed blots, and were any specific details provided about the molecular effect of the A53T ␣-synuclein variant on PGC-1␣ activity?

Based on the information provided in the literature context, the original text describing the densitometric analysis system used for the probed blots was: "The probed blots were then densitometrically analyzed using a QuantityOne 710 System (Bio-Rad)." Regarding the molecular effect of the A53T ␣-synuclein variant on PGC-1␣ activity, the context indicated that the variant had a gain-of-function effect, suggesting that it enhances PGC-1␣ activity in an abnormal manner.
Based on the information provided in the literature context, what was the original text describing the co-transfection procedure in the PGC-1␣ Activity Assay, and were any specific details provided about the image acquisition and analysis methods for autophagy measurements?

Based on the information provided in the literature context, the original text describing the co-transfection procedure in the PGC-1␣ Activity Assay was: "Neurons were co-transfected with a fusion protein that connected the yeast Gal4 DNA binding domain with full-length PGC-1␣ on the second day after plating, together with an appropriate Gal4-UAS-luciferase reporter and A53T ␣-synuclein." Regarding image acquisition and analysis methods for autophagy measurements, the context mentioned that these were used but did not provide specific details about the methods.
Based on the information provided in the literature context, what was the original text describing the statistical analysis of the interaction between treatments, and were any specific details provided about the validation controls for pathogenic/likely pathogenic or benign/likely benign variants?

Based on the information provided in the literature context, the original text describing the statistical analysis of the interaction between treatments was: "A two-way ANOVA was used to analyze the interaction between treatments." Regarding validation controls for pathogenic/likely pathogenic or benign/likely benign variants, there were no specific details provided in the given context.
Based on the information provided in the literature context, what was the original text describing the use of EGFP as a control in the mitochondrial density experiments, and were any specific details provided about the readout description for the A53T ␣-synuclein variant in the PGC-1␣ Activity Assay?

Based on the information provided in the literature context, the original text describing the use of EGFP as a control in the mitochondrial density experiments was: "control in the LC3 experiments and EGFP in the mitochondrial density experiments when necessary." Regarding the readout description for the A53T ␣-synuclein variant in the PGC-1␣ Activity Assay, the context indicated that the variant had an abnormal effect with a gain-of-function molecular effect, but no further specific details were provided about the readout description beyond this characterization.
Based on the information provided in the literature context, what was the original text describing the calculation of transfection efficiency, and were any specific details provided about the statistical analysis methods used?

Based on the information provided in the literature context, the original text describing the calculation of transfection efficiency was: "In addition, EGFP was cotransfected with the desired shRNA to calculate the transfection efficiency." Regarding specific details about the statistical analysis methods used, the context provided the following: "t test and one-way ANOVA, followed by a Newman-Keuls posthoc test or Kruskal-Wallis test, followed by a Dunn's test were then used to compare the differences between the samples and the control group. A two-way ANOVA was used to analyze the interaction between treatments."
Based on the information provided in the literature context, what was the original text describing the control settings in the shRNA experiments, and were any specific details provided about the thresholds for normal and abnormal readouts?

Based on the information provided in the literature context, the original text describing the control settings in the shRNA experiments was: "In the shRNA experiments, a plasmid encoding scrambled shRNA was used as a control. In addition, EGFP was cotransfected with the desired shRNA to calculate the transfection efficiency." Regarding specific details about the thresholds for normal and abnormal readouts, there were no such details mentioned in the provided context.
Based on the information provided in the literature context, what was the original text describing the densitometric analysis system used for the probed blots, and were any specific details provided about the molecular effect of the A53T ␣-synuclein variant on PGC-1␣ activity?

Based on the information provided in the literature context, the original text describing the densitometric analysis system used for the probed blots was: "The probed blots were then densitometrically analyzed using a QuantityOne 710 System (Bio-Rad)." Regarding the molecular effect of the A53T ␣-synuclein variant on PGC-1␣ activity, the context indicated that the variant had a gain-of-function effect, suggesting that it enhances PGC-1␣ activity in an abnormal manner.
Based on the information provided in the literature context, what was the original text describing the co-transfection procedure in the PGC-1␣ Activity Assay, and were any specific details provided about the image acquisition and analysis methods for autophagy measurements?

Based on the information provided in the literature context, the original text describing the co-transfection procedure in the PGC-1␣ Activity Assay was: "Neurons were co-transfected with a fusion protein that connected the yeast Gal4 DNA binding domain with full-length PGC-1␣ on the second day after plating, together with an appropriate Gal4-UAS-luciferase reporter and A53T ␣-synuclein." Regarding image acquisition and analysis methods for autophagy measurements, the context mentioned that these were used but did not provide specific details about the methods.
Based on the information provided in the literature context, what was the original text describing the statistical analysis of the interaction between treatments, and were any specific details provided about the validation controls for pathogenic/likely pathogenic or benign/likely benign variants?

Based on the information provided in the literature context, the original text describing the statistical analysis of the interaction between treatments was: "A two-way ANOVA was used to analyze the interaction between treatments." Regarding validation controls for pathogenic/likely pathogenic or benign/likely benign variants, there were no specific details provided in the given context.
Based on the information provided in the literature context, what was the original text describing the use of EGFP as a control in the mitochondrial density experiments, and were any specific details provided about the readout description for the A53T ␣-synuclein variant in the PGC-1␣ Activity Assay?

Based on the information provided in the literature context, the original text describing the use of EGFP as a control in the mitochondrial density experiments was: "control in the LC3 experiments and EGFP in the mitochondrial density experiments when necessary." Regarding the readout description for the A53T ␣-synuclein variant in the PGC-1␣ Activity Assay, the context indicated that the variant had an abnormal effect with a gain-of-function molecular effect, but no further specific details were provided about the readout description beyond this characterization.
Based on the information provided in the literature context, what was the original text describing the calculation of transfection efficiency, and were any specific details provided about the statistical analysis methods used?

Based on the information provided in the literature context, the original text describing the calculation of transfection efficiency was: "In addition, EGFP was cotransfected with the desired shRNA to calculate the transfection efficiency." Regarding specific details about the statistical analysis methods used, the context provided the following: "t test and one-way ANOVA, followed by a Newman-Keuls posthoc test or Kruskal-Wallis test, followed by a Dunn's test were then used to compare the differences between the samples and the control group. A two-way ANOVA was used to analyze the interaction between treatments."
Based on the information provided in the literature context, what was the original text describing the control settings in the shRNA experiments, and were any specific details provided about the thresholds for normal and abnormal readouts?

Based on the information provided in the literature context, the original text describing the control settings in the shRNA experiments was: "In the shRNA experiments, a plasmid encoding scrambled shRNA was used as a control. In addition, EGFP was cotransfected with the desired shRNA to calculate the transfection efficiency." Regarding specific details about the thresholds for normal and abnormal readouts, there were no such details mentioned in the provided context.
Based on the information provided in the literature context, what was the original text describing the densitometric analysis system used for the probed blots, and were any specific details provided about the molecular effect of the A53T ␣-synuclein variant on PGC-1␣ activity?

Based on the information provided in the literature context, the original text describing the densitometric analysis system used for the probed blots was: "The probed blots were then densitometrically analyzed using a QuantityOne 710 System (Bio-Rad)." Regarding the molecular effect of the A53T ␣-synuclein variant on PGC-1␣ activity, the context indicated that the variant had a gain-of-function effect, suggesting that it enhances PGC-1␣ activity in an abnormal manner.
Based on the information provided in the literature context, what was the original text describing the co-transfection procedure in the PGC-1␣ Activity Assay, and were any specific details provided about the image acquisition and analysis methods for autophagy measurements?

Based on the information provided in the literature context, the original text describing the co-transfection procedure in the PGC-1␣ Activity Assay was: "Neurons were co-transfected with a fusion protein that connected the yeast Gal4 DNA binding domain with full-length PGC-1␣ on the second day after plating, together with an appropriate Gal4-UAS-luciferase reporter and A53T ␣-synuclein." Regarding image acquisition and analysis methods for autophagy measurements, the context mentioned that these were used but did not provide specific details about the methods.
Based on the information provided in the literature context, what was the original text describing the statistical analysis of the interaction between treatments, and were any specific details provided about the validation controls for pathogenic/likely pathogenic or benign/likely benign variants?

Based on the information provided in the literature context, the original text describing the statistical analysis of the interaction between treatments was: "A two-way ANOVA was used to analyze the interaction between treatments." Regarding validation controls for pathogenic/likely pathogenic or benign/likely benign variants, there were no specific details provided in the given context.
Based on the information provided in the literature context, what was the original text describing the use of EGFP as a control in the mitochondrial density experiments, and were any specific details provided about the readout description for the A53T ␣-synuclein variant in the PGC-1␣ Activity Assay?

Based on the information provided in the literature context, the original text describing the use of EGFP as a control in the mitochondrial density experiments was: "control in the LC3 experiments and EGFP in the mitochondrial density experiments when necessary." Regarding the readout description for the A53T ␣-synuclein variant in the PGC-1␣ Activity Assay, the context indicated that the variant had an abnormal effect with a gain-of-function molecular effect, but no further specific details were provided about the readout description beyond this characterization.
Based on the information provided in the literature context, what was the original text describing the calculation of transfection efficiency, and were any specific details provided about the statistical analysis methods used?

Based on the information provided in the literature context, the original text describing the calculation of transfection efficiency was: "In addition, EGFP was cotransfected with the desired shRNA to calculate the transfection efficiency." Regarding specific details about the statistical analysis methods used, the context provided the following: "t test and one-way ANOVA, followed by a Newman-Keuls posthoc test or Kruskal-Wallis test, followed by a Dunn's test were then used to compare the differences between the samples and the control group. A two-way ANOVA was used to analyze the interaction between treatments."
Based on the information provided in the literature context, what was the original text describing the control settings in the shRNA experiments, and were any specific details provided about the thresholds for normal and abnormal readouts?

Based on the information provided in the literature context, the original text describing the control settings in the shRNA experiments was: "In the shRNA experiments, a plasmid encoding scrambled shRNA was used as a control. In addition, EGFP was cotransfected with the desired shRNA to calculate the transfection efficiency." Regarding specific details about the thresholds for normal and abnormal readouts, there were no such details mentioned in the provided context.
Based on the information provided in the literature context, what was the original text describing the densitometric analysis system used for the probed blots, and were any specific details provided about the molecular effect of the A53T ␣-synuclein variant on PGC-1␣ activity?

Based on the information provided in the literature context, the original text describing the densitometric analysis system used for the probed blots was: "The probed blots were then densitometrically analyzed using a QuantityOne 710 System (Bio-Rad)." Regarding the molecular effect of the A53T ␣-synuclein variant on PGC-1␣ activity, the context indicated that the variant had a gain-of-function effect, suggesting that it enhances PGC-1␣ activity in an abnormal manner.
Based on the information provided in the literature context, what was the original text describing the co-transfection procedure in the PGC-1␣ Activity Assay, and were any specific details provided about the image acquisition and analysis methods for autophagy measurements?

Based on the information provided in the literature context, the original text describing the co-transfection procedure in the PGC-1␣ Activity Assay was: "Neurons were co-transfected with a fusion protein that connected the yeast Gal4 DNA binding domain with full-length PGC-1␣ on the second day after plating, together with an appropriate Gal4-UAS-luciferase reporter and A53T ␣-synuclein." Regarding image acquisition and analysis methods for autophagy measurements, the context mentioned that these were used but did not provide specific details about the methods.
Based on the information provided in the literature context, what was the original text describing the statistical analysis of the interaction between treatments, and were any specific details provided about the validation controls for pathogenic/likely pathogenic or benign/likely benign variants?

Based on the information provided in the literature context, the original text describing the statistical analysis of the interaction between treatments was: "A two-way ANOVA was used to analyze the interaction between treatments." Regarding validation controls for pathogenic/likely pathogenic or benign/likely benign variants, there were no specific details provided in the given context.
Based on the information provided in the literature context, what was the original text describing the use of EGFP as a control in the mitochondrial density experiments, and were any specific details provided about the readout description for the A53T ␣-synuclein variant in the PGC-1␣ Activity Assay?

Based on the information provided in the literature context, the original text describing the use of EGFP as a control in the mitochondrial density experiments was: "control in the LC3 experiments and EGFP in the mitochondrial density experiments when necessary." Regarding the readout description for the A53T ␣-synuclein variant in the PGC-1␣ Activity Assay, the context indicated that the variant had an abnormal effect with a gain-of-function molecular effect, but no further specific details were provided about the readout description beyond this characterization.
Based on the information provided in the literature context, what was the original text describing the calculation of transfection efficiency, and were any specific details provided about the statistical analysis methods used?

Based on the information provided in the literature context, the original text describing the calculation of transfection efficiency was: "In addition, EGFP was cotransfected with the desired shRNA to calculate the transfection efficiency." Regarding specific details about the statistical analysis methods used, the context provided the following: "t test and one-way ANOVA, followed by a Newman-Keuls posthoc test or Kruskal-Wallis test, followed by a Dunn's test were then used to compare the differences between the samples and the control group. A two-way ANOVA was used to analyze the interaction between treatments."
Based on the information provided in the literature context, what was the original text describing the control settings in the shRNA experiments, and were any specific details provided about the thresholds for normal and abnormal readouts?

Based on the information provided in the literature context, the original text describing the control settings in the shRNA experiments was: "In the shRNA experiments, a plasmid encoding scrambled shRNA was